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| INTRODUCTION
While its role is most understood in the context of T-cell differentiation, the T-box transcriptional factor T-bet also plays an important role in B-cell differentiation and is frequently expressed in neoplastic human B cells. 1, 2 T-bet induction in B cells requires antigen-specific cross-linking of the B-cell receptor as well as type I/II IFN-mediated or IL-12-family receptormediated activation of STAT1 or STAT4 3, 4 in combination with TLR signalling. 5, 6 Once expressed, T-bet appears to regulate Ig class switching, 3, [6] [7] [8] [9] B-cell IFNγ production, 3, 4 and differentiation into antiviral-effector ADCC- 
| MATERIALS AND METHODS

| Patients
Subjects and controls were recruited from the Gastroenterology 
| Cell isolation and preparation
One hundred to one hundred and fifty millilitre of peripheral blood and 1% penicillin/streptomycin (Invitrogen).
| Antibodies and flow cytometry
All data were acquired on FACSCanto ( 
| Re-induction of T-bet expression
| Statistical analysis
Median values for clinical and immunologic parameters were compared using Wilcoxon signed-rank test, the nonparametric Kruskal-Wallis or Wilcoxon rank sum test. All statistical analyses were performed using JMP Pro 12 (SAS Institute Inc, Cary, NC, USA). P-values of <.05 were considered significant.
| RESULTS
| Patient characteristics
The study cohort comprised of 49 subjects, 11 healthy donors, eight patients with cirrhosis due to non-HCV-related cause, eight HCV patients without advanced fibrosis (based on Fibrosure F0-1, Fibroscan<9 kPA, or Ishak Fibrosis Score<3/6), 13 with HCV and liver cirrhosis and nine with HCV, cirrhosis and hepatocellular carcinoma (Table 1) . Eight HCV patients with cirrhosis were observed during direct-acting antiviral (DAA) therapy; all eight were successfully cured with standard genotype-specific all-oral therapies (three with sofosbuvir plus ribavirin for 12 weeks, five with ledipasvir/sofosbuvir for 12 weeks). Patients with cirrhosis, particularly those with cancer, were slightly older than healthy donors (median age 62 versus 55 years, P=.04) but similar in age to non-HCV cirrhotic patients that served as an additional control group. As expected due to portal hypertension, median platelet counts were lower in the cirrhosis subgroups but patients were in general well compensated with normal serum total bilirubin and albumin levels.
| Chronic hepatitis C infection is associated with increased frequency of class-switched T-bet + B cells with a tissue-like memory phenotype
The gating strategy for identifying B cells and quantifying T-bet is shown in Figure 1A . 
T A B L E 1 Baseline patient characteristics
| Evidence for antigen-specific regulation of Tbet expression
To test whether or not T-bet expression in B cells is regulated by HCV viraemia, we first exposed post-SVR12 convalescent B cells from cured patients to autologous pretreatment viremic or post-treatment aviremic plasma. As shown in Figure 5A , there was a statistically significant increase in T-bet expression after exposure of convalescent B cells to autologous viremic plasma (median 7.0% v. 4 
.3%, P=.009).
This increase did not appear to be mediated by immune complexes, as blockade of B-cell Fc receptors had not impact on T-bet upregulation ( Figure 5B ). The upregulation of T-bet was sequence-specific; 
| DISCUSSION
Chronic hepatitis C (HCV) infection in humans is
